Merck KGaA and Pfizer Inc.announced that the FDA has accepted for Priority Review the Biologics License Application (BLA) for avelumab,...
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).
Merck Inc announced that the FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA)...
Avelumab is a promising new therapeutic agent for patients with metastatic Merkel cell carcinoma, a rare and aggressive type of neuroendocrine tumor of the skin.
The National Institute for Health and Care Excellence (NICE) has published draft guidelines recommending Bavencio (avelumab), from Merck KGaA and...
Incyte announced that the FDA has approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zynyz, intended for the treatment of Merkel cell carcinoma.
Merck and Pfizer Inc. announced that the European Commission (EC) has grantedmarketing authorization for Bavencio (avelumab) as a monotherapy for...
Merck KGaA and Pfizer Inc. announced that the European Medicines Agency (EMA) has validated for review Merck�s Marketing Authorization Application...